Literature DB >> 3367560

Idiopathic membranous nephropathy: the natural history of untreated patients.

J V Donadio1, V E Torres, J A Velosa, R D Wagoner, K E Holley, M Okamura, D M Ilstrup, C P Chu.   

Abstract

We reviewed the diagnostic features and clinical course of 140 patients with idiopathic membranous nephropathy who had their index renal biopsies performed at the Mayo Clinic between 1972 and 1984. There were 93 males and 47 females (average age, 50.8 +/- 17 years); 116 patients (83%) had the nephrotic syndrome and 42 (30%) were hypertensive at diagnosis. Eighty-nine patients were not treated with corticosteroid or immunosuppressive drugs and 51 patients were treated mainly with short-term courses of prednisone alone; a minority of patients also received meclofenamate, cyclophosphamide, azathioprine, or chlorambucil. Five-year survival, including patients who received dialysis or a renal transplant, was 85%, 75% at 10 years, and no different from expected survival; there was no difference between untreated and treated groups. Also, there were no differences in the outcomes of renal function and protein excretion between untreated and treated patients. Among 28 patients (20%) who developed end-stage renal disease, 17 showed rapid progression within 2.5 years after diagnosis. Fifteen of the 17 patients were males; all were severely nephrotic and had impaired renal function at diagnosis. Only 1 of 24 patients with nonnephrotic proteinuria at index renal biopsy progressed to end-stage renal disease. Overall, a level of baseline proteinuria of 10 g or more per 24 hours and variable blood pressure control in hypertensive patients were associated with renal progression.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3367560     DOI: 10.1038/ki.1988.56

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  42 in total

Review 1.  Medical decision-making in membranous nephropathy: how to use limited clinical research evidence in patient management.

Authors:  Hirokazu Imai
Journal:  Clin Exp Nephrol       Date:  2005-09       Impact factor: 2.801

2.  Antifibrotic effect of tamoxifen in a model of progressive renal disease.

Authors:  Humberto Dellê; José Roberto C Rocha; Rita C Cavaglieri; José Mauro Vieira; Denise M A C Malheiros; Irene L Noronha
Journal:  J Am Soc Nephrol       Date:  2011-11-03       Impact factor: 10.121

Review 3.  Membranous nephropathy. Insights from Heymann nephritis.

Authors:  T Cavallo
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

Review 4.  Glomerulonephritis: diagnosis and treatment.

Authors:  P D Mason; C D Pusey
Journal:  BMJ       Date:  1994-12-10

5.  Membranous Nephropathy: Quantifying Remission Duration on Outcome.

Authors:  Daniel C Cattran; Esther D Kim; Heather Reich; Michelle Hladunewich; S Joseph Kim
Journal:  J Am Soc Nephrol       Date:  2016-10-18       Impact factor: 10.121

6.  Anti-phospholipase A₂ receptor antibodies in recurrent membranous nephropathy.

Authors:  A Kattah; R Ayalon; L H Beck; S Sethi; D G Sandor; F G Cosio; M J Gandhi; E C Lorenz; D J Salant; F C Fervenza
Journal:  Am J Transplant       Date:  2015-03-12       Impact factor: 8.086

7.  Long-term prognosis of chronic glomerulonephritis.

Authors:  S I Ryabov; V V Stavskaya
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

Review 8.  Rituximab therapy for membranous nephropathy: a systematic review.

Authors:  Andrew S Bomback; Vimal K Derebail; Julie G McGregor; Abhijit V Kshirsagar; Ronald J Falk; Patrick H Nachman
Journal:  Clin J Am Soc Nephrol       Date:  2009-03-11       Impact factor: 8.237

9.  Membranous glomerulonephritis in rheumatoid arthritis unrelated to gold, D-penicillamine or other connective tissue disease.

Authors:  L P Zarza; E N Sanchez; P A Acin; J M Ara; J G Baños
Journal:  Clin Rheumatol       Date:  1996-07       Impact factor: 2.980

10.  Differential effects of 17beta-estradiol and of synthetic progestins on aldosterone-salt-induced kidney disease.

Authors:  Paula-Anahi Arias-Loza; Melanie Muehlfelder; Susan A Elmore; Robert Maronpot; Kai Hu; Hartmut Blode; Christa Hegele-Hartung; Karl Heinrich Fritzemeier; Georg Ertl; Theo Pelzer
Journal:  Toxicol Pathol       Date:  2009-12       Impact factor: 1.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.